Materials and Methods
MCL cell lines Granta-519, Jeko-1 Rec-1 and Z-138 were provided by the DSMZ (Braunschweig, Germany) or the respective primary investigator. Experiments were performed in triplicates. MCL cells were treated with obinutuzumab and / or rituximab at 10 µg/ml. Cell viability was analysed by "ViCell Cell Viability Analyzer" tests at 0h, 24h, 48h and 72h. Fractional product was calculated: synergism > 0,1; antagonism < -0,1. Cell preparation for Affymetrix analysis was performed according to the manufacturer's protocol. The cells were treated for 4h with 10 µg/ml obinutuzumab, rituximab, human anti-IgG antibody (isotype control) and PBS (buffer control, pH 7.2, 7µl). Genechip HU U133 Plus 2.0 was used for cRNA microarray analysis. All samples fulfilled the filter criteria: fold change > 1, mean > 100, call > 0.5 and t-test pvalue < 0.05. Networks were generated through the use of IPA (Ingenuity® Systems). 
Results and discussion

In-vitro effects of obinutuzumab and rituximab
Obinutuzumab induced a higher reduction in cell viability in each MCL cell line than rituximab. (Figure 1 ) Combination experiments suggested the competitive binding of the two antibodies due to overlapping epitopes on the target cells and resulted in a lower cytotoxicity than obinutuzumab alone, according to fractional product calculations (Granta-519: -0.56; Jeko-1: -0.14; Rec-1: -0.44; Z-138: -0.18). Due to the high rate of cell kill in Granta-519, micro-array data collection was not possible.
Commonly deregulated genes after both mono-treatments
19 of the 21 commonly deregulated genes were also deregulated after combination therapy. Cytokines CCL3 and CCL4 are upregulated in both mono-experiments.
Cittera et al. identified the upregulation of cytokines CCL3 and CCL4 after rituximab administration, presumably involved in the eradication of lymphoma cells. Francke et al. were able to show that treatment with anti-CD20 and B-cell receptor (BCR) mAbs resulted in a similar deregulation of the transcriptome in multiple lymphoma cell lines. Both mAb treatments share an upregulation of cancer suppressor gene EGR-1 that also belongs to the BCR signalling pathway, known to down-regulate Survivin, an anti-apoptotic molecule, and to induce caspase signalling resulting in apoptosis induction. Survivin was silenced by siRNA in MCL cell line Jeko-1, followed by a reduction in proliferation.
Both treatments upregulated DUSP2, a gene that belongs to the ERK/MAPK pathway that plays a crucial role in growth suppression.
( An up-regulated EGR-1 gene induces a down-regulation of Survivin. In consequence, down-regulation of Survivin is followed by an activation of caspase-induced apoptosis. In addition, Chen et al. were able to show that JUN and EGR-1 are key role players in the bortezomib induced apoptosis downstream pathway in MM. Upregulated NFKBIE encodes for a protein known to bind to NF-κB components targeting the complex for degradation. As a result, the NF-κB complex is prevented from deregulating genes in the nucleus and promoting cell proliferation. The encoded protein I B is deactivated by phosphorylation mediated by IκB-kinases. Apart from NF-B-signalling, together with NFATC1, NFKBIE is involved in PI3K-signalling.
( 
Deregulated genes by combination treatment
The combination experiments disclosed 37 up-and 6 downregulated genes. 16 genes were unique to both rituximab mono-and combination treatments, while obinutuzumab and combination exposure shared only two uniquely deregulated genes, indicating a rituximab-like expression pattern in combination experiments, similar to the in-vitro findings. Both mAbs have approximately the same affinity (obinutuzumab: 4.0 nM vs. rituximab: 4.5 nM K D value) to the human CD20. The invitro effect is related to the overlapping epitopes, although it may be argued that on a particular cell CD20 molecules can be occupied by rituximab and obinutuzumab simultaneously. (Mossner, et al 2010) Niederfellner et al. hypothesized that the excess binding sites for type I mAbs are either due to an abundance of various CD20 molecules that are targeted by either mAb type or due to steric binding orientations and elbow-hinge angle conformations. Furthermore, the CD20 epitope displays twice as many binding sites for type I mAbs as for type II. These findings indicate that a combination with obinutuzumab may be more promising than rituximab in MCL patients. However, patients recently pre-treated with rituximab should only be exposed to obinutuzumab after rituximab levels have decreased. The understanding of the deregulation patterns presented in our work might guide more rational approaches for new combination experiments in MCL. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 F o r P e e r R e v i e w 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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In-vitro effects of obinutuzumab and rituximab
Commonly deregulated genes after both mono-treatments
19 of the 21 commonly deregulated genes were also deregulated after combination therapy. Cytokines CCL3 and CCL4 are upregulated in both mono-experiments. An up-regulated EGR-1 gene induces a down-regulation of Survivin. In consequence, down-regulation of Survivin is followed by an activation of caspase-induced apoptosis. In addition, Chen et al. were able to show that JUN and EGR-1 are key role players in the bortezomib induced apoptosis downstream pathway in MM. Upregulated NFKBIE encodes for a protein known to bind to NF-κB components targeting the complex for degradation. As a result, the NF-κB complex is prevented from deregulating genes in the nucleus and promoting cell proliferation. The encoded protein I B is deactivated by phosphorylation mediated by IκB-kinases. Apart from NF-B-signalling, together with NFATC1, NFKBIE is involved in PI3K-signalling. (Figure 2Table 1b) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Vogler argues that the development of small molecule inhibitors for this target gene might contribute to anti-tumour therapy. (Figure 2Table 1c) 
Uniquely deregulated genes after rituximab mono-treatment
Deregulated genes by combination treatment
The combination experiments disclosed 37 up-and 6 downregulated genes. 16 genes were unique to both rituximab mono-and combination treatments, while molecules that are targeted by either mAb type or due to steric binding orientations and elbow-hinge angle conformations. Furthermore, the CD20 epitope displays twice as many binding sites for type I mAbs as for type II. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
